🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — May 05, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (though including cross-sector disclosures), dominant themes include mixed financial results in biotechs and medtech with YoY loss narrowing via cost cuts (e.g., Editas -67%, Precision Bio rev +>100x), revenue growth in diagnostics/pharma (IDEXX +14% YoY, Pfizer non-COVID +7%), and leadership transitions (Integra CEO change). Period-over-period trends show 7/12 key healthcare firms with organic revenue growth averaging +6% YoY but margin volatility (e.g., Integra gross +460bps, BrightView net income -73%); financials/funds exhibit NII growth offset by higher provisions (Amalgamated +13.5% NII but prov +>20x). Forward-looking catalysts cluster in H1-H2 2026 (FDA PDUs, trials, AGMs), with capital returns via buybacks (BrightView 1.1M shares, DFIN $28M) signaling confidence amid cash burn. Portfolio-level patterns reveal biotech efficiency gains (R&D cuts 20-34% YoY) contrasting energy funds' revenue declines (avg -30% YoY), implying healthcare resilience vs cyclical weakness. Critical implications: Biotech turnarounds offer alpha; monitor proxy fights (Pacira June 9) and guidance reaffirms (Pfizer FY $59.5-62.5B).

18 high priority 32 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 05, 2026

Across 12 DEF 14A proxy filings dated around May 5, 2026, overarching themes include routine annual meetings for director elections (9/12), auditor ratifications (10/12), say-on-pay advisory votes (5/12), and equity incentive plan approvals, alongside special actions like share increases (Orgenesis, FibroBiologics), SPAC deadline extensions (Range Capital), reverse stock splits (Beyond Air), and reincorporations (Sonoma). Key period-over-period trends: CrowdStrike's FY2026 revenue +22% YoY to $4.81B, ARR +24% YoY to $5.25B, FCF margin 26%; FONAR exec comp down 21% YoY for CEO to $295k while flat for another; Range Capital trust +5.6% to $121.9M from post-IPO $115.6M. Critical developments: delisting risks (Beyond Air), dilution proposals (4/12 filings), and strong governance signals (Workday). Market implications: heightened dilution risks in biotechs/SPACs signal bearish near-term pressure, while SaaS leaders like CrowdStrike show portfolio-level growth outperformance; neutral sentiment dominates (8/12), but vote outcomes could drive volatility ahead of summer meetings.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 05, 2026

Two S-4 filings on May 05, 2026, underscore active merger-driven paths in the US IPO pipeline, with ATII Holdings advancing a SPAC business combination between Forge Nano Inc. and Archimedes Tech SPAC Partners II Co., while Mountain Holding (New Equitable) pursues consolidation of Corebridge Financial ($385B AUM) and Equitable Holdings (>$1.1T AUM) into a new NYSE-listed EQH entity. Period-over-period data reveals stable customer concentration at ATII (two major revenue customers in 2025 vs. two in 2024), indicating revenue reliability but no broader growth metrics available across filings. Critical developments include ATII's lock-up expiration today (2026-05-05) for sponsors, insiders, and Forge Nano holders, and Mountain's targeted merger close by year-end 2026 pending multi-regulator approvals. Neutral sentiment at ATII contrasts with mixed at Mountain due to execution risks detailed from page 44. Portfolio-level patterns highlight merger/SPAC reliance for public access, with scale in financials (> $1.485T combined AUM) but regulatory hurdles prevalent. Market implications favor monitoring unlock volatility and approval catalysts for near-term trading alpha.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — May 05, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus), dominant themes include robust revenue and PAT growth in automotive/manufacturing (e.g., Mahindra & Mahindra +25% FY26 revenue YoY), margin expansions amid volume challenges in consumer goods (Energizer +360 bps gross margin), and SPAC IPO momentum (ARC Group $105M, CH4 $200M) signaling M&A appetite in tech/healthcare/logistics and nature-based assets. Period-over-period trends show average revenue growth of ~15-25% YoY in 12/20 detailed quarterly reporters (e.g., DigitalOcean +22%, Duolingo +27%), but net income volatility with 6/15 mixed/negative due to one-offs (Grayscale -51% NAV QoQ, BrightView net income -73% YoY). Crypto assets tanked (GDLC unrealized losses $463M), while mergers like Equitable/Corebridge advance with $500M+ synergies targeted YE2026. Capital allocation leans shareholder-friendly: dividend hikes (Mahindra +30% to ₹33/share), buybacks (Gartner $535M, BrightView 1.1M shares), but risks cluster in Indian insolvencies/defaults (Dharani Sugars 57Cr principal default, Bihar Sponge IBC notice). Guidance largely raised (InTest FY26 rev $130-135M, DigitalOcean +26% FY26), building Q2-H2 2026 catalysts; portfolio-level: outperformance in non-cyclical tech/auto vs. underperformance in utilities/crypto.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 05, 2026

Across 50 Q1 2026 10-Q filings, sentiment is overwhelmingly mixed (46/50), with revenue growth in 35/50 companies averaging +18% YoY (outliers like Fabrinet +39%, EVgo +45%, Paymentus +30%), but offset by net income declines or widened losses in 28/50 due to expense inflation (avg +20% YoY in SG&A/R&D) and higher interest/provisions. Cash flows show volatility: operating cash up YoY in 22/50 (e.g., Duolingo +43%, Gartner +25%), but down or negative in 18/50 amid inventory/receivable builds. Capital allocation leans shareholder-friendly with buybacks in 12 companies (e.g., Gartner $535M, TopBuild via share reduction) and dividend hikes (e.g., Amalgamated +21%, Tompkins +8%), while debt reductions signal deleveraging in 10 firms. Financials exhibit NII growth (+10% avg) but rising provisions; tech/energy mixed with volume gains but derivative/opex hits. Portfolio implication: Favor high-growth outliers like Duolingo/Shopify for momentum, monitor cash burn in biotechs/loss-makers; sector rotation toward profitable industrials (AGCO, Fabrinet). No major insider patterns noted, but buyback aggression flags conviction in mature names.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 05, 2026

Four Nasdaq-listed micro-cap companies—PLAYSTUDIOS (MYPS), VenHub Global (VHUB), Envirotech Vehicles (EVTV), and Versus Systems (VS)—face imminent delisting risks due to failures in meeting minimum bid price ($1.00) or stockholders' equity ($2.5M) requirements under Nasdaq rules, with notices issued in late April 2026. Common themes include prolonged sub-$1 bid prices for 30 consecutive days (PLAYSTUDIOS, VHUB) and equity deficits below $2.5M as of Dec 31, 2025 (EVTV, VS at $1.92M), signaling deteriorating financial health amid no reported YoY/QoQ revenue growth or margin expansions in enriched data. PLAYSTUDIOS secured a transfer to Nasdaq Capital Market on May 6 with a second 180-day window to Nov 2; VHUB has initial 180 days to Oct 27; EVTV and VS must submit compliance plans by June 13, potentially extending to Oct 26. Versus shows relative resilience with a mixed sentiment from a $1.7M equity infusion at 105% premium, while others remain negative. No insider buying detected across filings, underscoring low management conviction; portfolio-level pattern reveals 100% negative/mixed sentiment and high delisting materiality (9/10), urging avoidance of long exposure in Nasdaq small caps. Forward-looking plans like reverse splits offer potential catalysts but carry no compliance guarantees.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 05, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (38 new), distress signals cluster in micro-cap Nasdaq/NYSE compliance failures (7 companies citing bid price < $1 or equity < $2.5M), plant closures, and widening losses (e.g., Rayonier sales -10% YoY, net loss doubled), but are overshadowed by 20+ positive catalysts including M&A/divestitures (12 deals totaling $2B+ value), debt refinancings/extensions (8 instances extending maturities 3-5 years), equity offerings ($500M+ raised), and guidance raises (INTEST FY rev to $130-135M, DigitalOcean FY26 +26%, ONITY ROE 10-15%). Period trends show revenue growth averaging +18% YoY in reporting firms (e.g., INTEST +27%, Bowhead premiums +24%, DigitalOcean +22%), margin expansions in 6/15 cases (INTEST +400bps gross), but compressions/declines in others (BrightView Development EBITDA -44%, Rayonier op loss widened); no insider trades reported, capital allocation favors growth/reinvestment over buybacks/dividends. Portfolio-level: Small-cap distress creates short opportunities, while mid-caps pursue consolidation/deleveraging for resilience. Implications: Monitor delisting risks for downside, pivot to M&A plays for alpha amid improving liquidity.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — May 05, 2026

Across 36 filings in the USA Executive & Director Changes stream, a dominant theme is high executive turnover, particularly in finance roles (CFOs, controllers, accounting officers in 12 companies including Atlantic American, Kimberly-Clark, Core Scientific, CF Industries, Genesco, Portillo's), with 18 appointments and 14 departures, often neutral but featuring experienced hires signaling continuity. Embedded Q1/FY2026 earnings show mixed revenue trends (avg +3.5% YoY across 15 reporting firms, but declines in 7 like Energizer -3%, FTC Solar -17%, Primoris -5.4%), offset by margin expansions (e.g., Energizer +360bps, Emerson +320bps) and reaffirmed/raised guidance in 10 cases. Positive sentiments dominate leadership adds (e.g., Integra, iAnthus, CF Industries), while negatives cluster around disputes (B&G Foods). Portfolio-level: Margin resilience amid soft volumes; capital returns strong ($500M Klaviyo buyback, $2.2B Emerson). Implications: Opportunities in experienced leadership turnarounds, risks in finance churn; watch catalysts like earnings calls.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 05, 2026

The 35 filings in the 'USA Board Room Changes' stream reveal a wave of 25+ executive and board transitions, including 12 CEO/CFO appointments/resignations and 10+ director elections/additions, often featuring experienced hires amid mixed Q1 FY2026 earnings with average reported revenue growth of +6% YoY (Klaviyo +28% outlier, FTC Solar -17% low-end) and gross margin expansions in 4/10 reporting firms (Energizer +360bps standout). Declines in volumes/sales hit cyclical sectors (Energizer batteries -6.1%, Primoris Energy -13.8%), but Adjusted EBITDA grew +10% on average where disclosed, driven by organic expansions and acquisitions. Guidance was raised/reaffirmed in 8/12 cases (e.g., AdaptHealth revenue to $3.45-3.52B, Klaviyo to $1.514-1.522B), signaling management confidence post-changes; capital returns strong via $500M+ buybacks (Klaviyo, Emerson). Positive sentiment in 40% of filings tied to continuity hires (Integra Essig return), while neutral/negative in departures without successors (Portillo CFO). Portfolio implications: Healthcare and industrials show leadership stabilization for growth, consumer CFO churn flags execution risks. Overall, transitions lean positive for long-term execution, with near-term catalysts from earnings calls.

35 high priority 35 total filings
· daily

US Merger & Acquisition SEC Filings — May 05, 2026

The 16 filings reveal a surge in SPAC activity with 8 new IPOs, extensions, unit separations, and de-SPAC mergers targeting tech, AI, healthcare, logistics, and biofuels, signaling robust M&A momentum in high-growth sectors amid a May 2026 filing cluster. Key period-over-period trends include Avista Corp's Q1 2026 GAAP net income up 16% YoY to $92M ($1.11/share) and non-GAAP utility earnings up 11% to $91M, though electric margins dipped slightly QoQ; limited other operational comps highlight deal-driven focus over earnings. Critical developments feature Compass Diversified's $292.5M subsidiary sale for deleveraging to <1.0x leverage by June 30, multiple $60-105M SPAC IPOs, and high-value mergers like DMAA-PAGC at $1B EV and Applied Digital's 97%-owned ChronoScale spin-off. Portfolio-level patterns show positive sentiment in 9/16 filings (avg materiality 8.3/10), with SPACs dominating (50% of filings) and M&A completions/announcements in AI/data centers/biofuels, implying investor appetite for tech consolidation despite redemption risks in extensions like Pyrophyte's $1.29M outflow. Capital allocation leans toward deleveraging (CODI) and reinvestment via acquisitions (Exodus $30M, Oncotelic $20M IP), with no dividend/buyback shifts noted. Market implications: heightened takeover premiums and SPAC dry powder could drive 10-20% upside in targets, but monitor redemptions and leverage covenants.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 05, 2026

Overnight SEC filings for May 5, 2026 reveal a mixed Q1 2026 earnings landscape across 50 companies, with 12/20 major reporters showing revenue growth averaging +15% YoY (e.g., Ecovyst +50%, Terex +41% reported), but 8 experiencing declines averaging -5% (e.g., Ingredion -1%, Gartner -1.5%), amid margin expansions in 7 cases (+ avg 150bps, DuPont to 24.6%) offset by compressions in 6 (- avg 200bps, Atkore to 18.6%). Guidance raises in 6 firms (DuPont FY sales $7.15-7.22B, ADM EPS $4.15-4.70, Ecovyst EBITDA $180-195M) signal confidence, while capital allocation favors buybacks ($535M Gartner, $275M DuPont ASR imminent) and dividends across 8 names. M&A/divestitures dominate (DuPont Aramids $1.2B sale, Expro $215M acquisition Q3 close, Coterra/Devon merger May 7 close), with SPAC IPOs (CH4 $200M, ARC $105M) adding liquidity. Energy sector shines with production up (Black Stone +16% QoQ), merger approvals; industrials mixed on costs/tariffs. Portfolio implication: overweight raised-guidance industrials/chemicals, monitor energy M&A catalysts for pre-market pops.

16 high priority 34 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 04, 2026

The May 04, 2026 FDA approval period in biotech small-cap stream delivered 10 'Other' approvals (0 NMEs, 0 biosimilars, 0 label expansions per mix), dominated by 9 biosimilar approvals and 1 NME, yielding 1 bullish and 9 neutral signals. No dominant therapeutic area theme emerged, though CNS/neurology saw clustering with biosimilars to OXCARBAZEPINE, VILOXAZINE HYDROCHLORIDE, CENOBAMATE, FLUVOXAMINE MALEATE, and DOXEPIN HYDROCHLORIDE. Highest-conviction signal is INSULIN GLARGINE-ALDY (LANGLARA) NME by SUNSHINE LAKE PHARMA CO LTD, signaling 5-year NCE exclusivity and diabetes market entry potential with high strength (8/10 materiality). Biosimilar entrants like APOTEX INC (SITAGLIPTIN) and AUROBINDO PHARMA LIMITED (CENOBAMATE) gain upside, balanced by bearish erosion risks for undisclosed originators (30-60% revenue potential over 2-3 years). Key risk/watch item: competitive dynamics from biosimilar launches pressuring neurology originator pricing power.

10 total filings
· daily

Orphan Drug Approvals — May 04, 2026

The FDA approved 1 Other drug in the Orphan stream (0 NMEs, 0 biosimilars, 0 label expansions) from May 04, 2026 to May 04, 2026, consisting solely of a label expansion for SELINEXOR by KARYOPHARM THERAPS. This bullish signal (strength 5/10, materiality 5/10) is the highest-conviction event, indicating positive execution for Karyopharm in the orphan space with potential to broaden SELINEXOR (XPOVIO)'s addressable market, though peak sales, exclusivity, pricing, and market position remain NOT_DISCLOSED. No dominant therapeutic area theme is present given the single approval. A key risk/watch item is Karyopharm's post-approval commercialization execution, as near-term catalysts are listed as N/A.

1 total filings
· daily

New Drug Approvals (Original) — May 04, 2026

The May 4, 2026 FDA approval period delivered 10 'Other' approvals (0 NME, 0 biosimilar, 0 label expansion per official mix), primarily comprising 9 biosimilar approvals across psychiatry, neurology, diabetes, hematology, and fertility, plus 1 NME approval for INSULIN GLARGINE-ALDY (LANGLARA) by SUNSHINE LAKE PHARMA CO LTD. No dominant therapeutic area theme clusters strongly, though neurology/epilepsy/ADHD sees multiple entries including OXCARBAZEPINE (UMEDICA LABS PVT), CENOBAMATE (AUROBINDO PHARMA LIMITED), and VILOXAZINE HYDROCHLORIDE (APPCO PHARMA LLC). Highest-conviction signal is the bullish (8/10 strength/materiality) NME for INSULIN GLARGINE-ALDY (LANGLARA), enabling SUNSHINE LAKE PHARMA CO LTD entry into the insulin/diabetes market with potential 5-year NCE exclusivity and sizable TAM upside. Key risk/watch item is competitive erosion to undisclosed originators from the biosimilar wave (e.g., SITAGLIPTIN by APOTEX INC, ELTROMBOPAG OLAMINE by AIZANT), balanced by bullish entry opportunities for generic sponsors.

10 total filings
· daily

New Federal Contractors — May 04, 2026

NASA Goddard Space Flight Center dominates with a single $351,035,113 cost-plus-fixed-fee obligation to ALCYON TECHNICAL SERVICES (ATS) JV, LLC, representing 100% civilian exposure and 0% defense-related contracts. The dominant agency theme is NASA civilian space systems engineering R&D (NAICS 541712, PSC R425), awarded as an 8(a) competed set-aside to this SBA Certified 8(a) Joint Venture and Economically Disadvantaged Women Owned Small Business. Highest-conviction signal is neutral (strength 3/10, materiality 2/10) due to set-aside nature limiting competitive moat signals and low overall materiality. $246,907,027 has been outlayed (70% progress) with $7,385,356,524 across 2690 subawards indicating substantial downstream activity. Key watch item: contract end date compliance by 2023-11-30 and remaining $104M obligation execution amid potential re-compete.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 04, 2026

A single significant contract modification totaling $351,035,113 in obligations was recorded, representing 100% civilian (NASA Goddard Space Flight Center) with 0/1 defense-related. ALCYON TECHNICAL SERVICES (ATS) JV, LLC, an SBA Certified 8(a) Joint Venture, received the cost-plus-fixed-fee modification for systems engineering services (NAICS 541712, PSC R425). The dominant agency theme is NASA civilian space R&D support, with a neutral highest-conviction signal (strength 3/10, materiality 2/10) reflecting mature execution ($246,907,027 outlayed of $351,035,113). Low pricing risk supports steady performance, but the contract's original end date of 2023-11-30 warrants monitoring for extensions. Massive subawards ($7,385,356,524 across 2690) indicate strong ecosystem flow-through. Overall, low conviction for institutional action in defense/aerospace portfolios.

1 total filings
· daily

Contract Deobligations Alert — May 04, 2026

A single Contract Deobligations Alert over the May 04, 2026 period flagged $351,035,113 in total obligations for ALCYON TECHNICAL SERVICES (ATS) JV, LLC's NASA Goddard Space Flight Center systems engineering contract. This is 0/1 defense-related, representing 100% civilian NASA exposure. The dominant theme is 8(a) set-aside R&D services in space systems engineering (NAICS 541712, PSC R425). The highest-conviction signal is neutral (strength 3/10, materiality 2/10), reflecting low-impact deobligation on a mature contract with $246,907,027 outlayed (70% execution) and $7,385,356,524 in 2690 subawards. Key watch item: post-2023-11-30 end date deobligations and subawards flow-through.

1 total filings
· daily

Contract Option Exercises — May 04, 2026

NASA Goddard Space Flight Center exercised options totaling $351,035,113 in obligations on a cost-plus-fixed-fee contract with ALCYON TECHNICAL SERVICES (ATS) JV, LLC, an SBA Certified 8(a) Joint Venture, for systems engineering services (NAICS 541712, PSC R425). This represents a 100% civilian agency award with 0 defense-related contracts, underscoring steady NASA spending in space systems R&D amid a neutral signal (avg strength 3.0/10). The dominant theme is sustained support for mission and instrument engineering at Goddard, performed in Greenbelt, MD, with $246,907,027 already outlayed and $7,385,356,524 in subawards across 2690 transactions. Highest-conviction signal is neutral continuation of this 8(a) competed set-aside from 2015 through 2023-11-30, implying low disruption risk but limited growth alpha. Key watch item: monitor outlay progress toward full $351M obligation and subawards execution, given the contract's end date has passed relative to the 2026 exercise period.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 04, 2026

NASA dominates this $351,035,113 obligation period with a single civilian mega-contract to ALCYON TECHNICAL SERVICES (ATS) JV, LLC, representing 100% civilian exposure (0/1 defense-related). The award funds systems engineering services (NAICS 541712, PSC R425) at Goddard Space Flight Center under an 8(a) competed set-aside, with $246,907,027 outlayed to date and $7,385,356,524 in 2690 subawards. Highest-conviction signal is neutral (3/10 strength, 2/10 materiality), reflecting steady but low-impact execution on this cost-plus-fixed-fee vehicle ending 2023-11-30. Key risk is monitoring post-contract execution given the 2026 data snapshot and massive subaward volume exceeding the prime obligation by 21x.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 04, 2026

The sole high-value federal grant obligation of $351,035,113 during May 04, 2026 to May 04, 2026, is 100% civilian (NASA) with 0% defense-related exposure. NASA Goddard Space Flight Center awarded this cost-plus-fixed-fee contract to ALCYON TECHNICAL SERVICES (ATS) JV, LLC, an SBA Certified 8(a) Joint Venture, for systems engineering services (NAICS 541712, PSC R425). The neutral signal (strength 3/10, materiality 2/10) reflects $246,907,027 outlayed to date on the $351M obligation, plus $7,385,356,524 across 2690 subawards, on an 8-year contract spanning 2015-2023. Dominant theme is civilian space R&D via 8(a) set-asides. Highest-conviction signal is steady but low-materiality execution for this small business JV. Key watch item: contract end date compliance by 2023-11-30 and remaining ~$104M obligation outlays.

1 total filings